For research use only
| Cat No. | ABC-X0034C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The HRAS (G13C) BAF3 cell line provides a high-fidelity model for tumor signaling research, suitable for drug response assessment and disease progression.
Human HRAS (G13C) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. HRAS (G13C) BAF3 mutant cell line is generated by stable integration of exogenous human HRAS gene harboring the G13C mutation into Ba/F3 host cells using our optimized transduction of lentiviral vectors.
Target
HRAS is a member of the RAS superfamily of GTPases that regulate cell signaling cascades, including RAF/MEK/ERK and PI3K/AKT pathways. The G13C mutation disrupts GTP hydrolysis, locking HRAS in a constitutively active conformation. This mutation is implicated in transformation, increased proliferation, and resistance to upstream inhibitors. AcceGen offers generation of stable overexpression and point-mutant cell lines tailored for molecular oncology studies. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0034C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The HRAS (G13C) BAF3 Cell Line provides a high-fidelity system for dissecting oncogenic HRAS signaling, assessing mutation-specific drug responses, and modeling disease progression. It is suitable for drug screening, biomarker validation, and mechanistic cancer research.